Sumit Aggarwal

Company: Eloxx Pharmaceuticals

Job title: Chief Executive Officer & President

Seminars:

Bringing Genetic Therapy to Rare Kidney Diseases 9:30 am

Developing ELX-02: New small molecule genetic therapy to treat Alport patients with nonsense mutations developed for superior PTC readthrough compared to Gentamicin. Focusing on rare kidney diseases Compelling proof of concept in Phase 2 study showing that in only 8 weeks ELX-02 treatment improved morphology by reducing podocyte foot process effacement in Alport Syndrome patients…Read more

day: Conference Day Two